Alexander V.
- Country
- Austria
- Department
- VIVIT Institute
Research Overview
- Effect of Orforglipron on Major Adverse Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
- Effect of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a): A Randomized, Placebo-Controlled Study
- Effect of Muvalaplin on Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: A Phase 3 Randomized Trial
Data & Insights
Has run more than one trial at 522 of 1189 partner sites.
Specializations
Metabolic Disorders
The investigator specializes in treating patients with Type 2 Diabetes and obesity, focusing on innovative therapeutic approaches for metabolic health management.
- Weight Management
- Metabolic Syndrome
- Glucose Control
Primary interest lies in exploring oral therapeutic options for patients with complex metabolic conditions.
Cardiovascular Health
Dedicated to understanding the intersection of cardiovascular diseases with metabolic disorders, particularly in high-risk populations.
- Cardiovascular Risk Management
- Preventive Cardiology
- Cardiometabolic Health
Focuses on comprehensive treatment approaches that address both cardiovascular and metabolic health outcomes.
Renal Medicine
Expertise in managing chronic kidney disease in conjunction with metabolic disorders, emphasizing integrated treatment strategies.
- Diabetic Nephropathy
- Renal Function
- Metabolic-Renal Interface
Specializes in therapeutic approaches that consider the complex relationship between kidney function and metabolic health.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.